Phase I study of H3B-6545 in patients (pts) with estrogen receptor-positive (ER plus ) breast cancer

被引：0

作者：

Ono, M. ^{[1
]}

Kogawa, T. ^{[1
]}

Kitano, S. ^{[1
]}

Shimoi, T. ^{[2
]}

Yamamoto, K. ^{[2
]}

Kobayashi, S. ^{[3
]}

Ichikawa, Y. ^{[3
]}

Yamaguchi, K. ^{[4
]}

Otake, Y. ^{[3
]}

Hojo, S. ^{[5
]}

Yonemori, K. ^{[2
]}

机构：

[1] Japanese Fdn Canc Res, Canc Inst Hosp, Adv Med Dev Ctr, Tokyo, Japan

[2] Natl Canc Ctr, Dept Med Oncol, Tokyo, Japan

[3] Eisai & Co Ltd, DHBL, Clin Evidence Generat Fulfillment, Japan & Asia Clin Dev,Dept Oncol, Tokyo, Japan

[4] Eisai & Co Ltd, DHBL, Clin Evidence Generat Fulfillment, Clin Pharmacol Sci Dept, Tokyo, Japan

[5] Eisai & Co Ltd, DHBL, Clin Evidence Generat Fulfillment, Clin Data Sci Dept, Tokyo, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

55O

引用

页码：S1487 / S1487

页数：1

共 50 条

[1] H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)
Hamilton, Erika P.
Pluard, Timothy J.
Wang, Judy S.
Morikawa, Aki
Johnston, Stephen R. D.
Dees, Elizabeth Claire
Vaklavas, Christos
Armstrong, Anne C.
Munster, Pamela N.
Unni, Nisha
Wright, Gail Lynn Shaw
Kayali, Fadi
Song, Tingting
Rong, Yuanxin
Yamaguchi, Kohei
Juric, Dejan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2 (HER2)-negative breast cancer, phase 1b study
Johnston, Stephen
Pluard, Timothy J.
Wang, Judy S.
Hamilton, Erika P.
Juric, Dejan
Scholz, Catherine R.
Hnitecki, Elizabeth
Dar, Sara
Gao, Lei
Cantagallo, Lisa
Korpal, Manav
Xiao, Jianjun Alan
Yu, Lihua
Sahmoud, Tarek
Gualberto, Antonio
CANCER RESEARCH, 2022, 82 (04)
[3] Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Johnston, Stephen R. D.
Pluard, Timothy J.
Wang, Judy S.
Hamilton, Erika P.
Juric, Dejan
Scholz, Catherine Rose
Hnitecki, Elizabeth
Gao, Lei
Cantagallo, Lisa
Korpal, Manav
Destenaves, Benoit
Xiao, Jianjun Alan
Zhang, Zhaojie
Pipas, J. Marc Marc
Yu, Lihua
Sahmoud, Tarek
Gualberto, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2-BC)
Majid, Oneeb
Xiao, Jianjun Alan
Sahmoud, Tarek
Yasuda, Sanae
Cantagallo, Lisa
Hamilton, Erika P.
Pluard, Timothy
Juric, Dejan
Gualberto, Antonio
Husseiin, Ziad
CANCER RESEARCH, 2021, 81 (04)
[5] H3B-6545+palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)
Johnston, Stephen R. D.
Pluard, Timothy J.
Wang, Judy S.
Hamilton, Erika P.
Song, Tingting
Rong, Yuanxin
Yamaguchi, Kohei
Juric, Dejan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
Hamilton, Erika P.
Wang, Judy S.
Pluard, Timothy J.
Johnston, Stephen R. D.
Morikawa, Aki
Dees, Elizabeth Claire
Jones, Robert Hugh
Haley, Barbara B.
Armstrong, Anne Caroline
Cohen, Adam Louis
Munster, Pamela N.
Wright, Gail Lynn Shaw
Kayali, Fadi
Korpal, Manav
Xiao, Jianjun Alan
Long, Jenny
Destenaves, Benoit
Gao, Lei
Gualberto, Antonio
Juric, Dejan
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer - A phase II study
Hamilton, Erika P.
Wang, Judy S.
Pluard, Timothy
Morikawa, Aki
Dees, E. Claire
Jones, Robert H.
Haley, Barbara
Armstrong, Anne
Cohen, Adam L.
Munster, Pamela
Wright, Gail S.
Kayali, Fadi
Cantagallo, Lisa
Korpal, Manav
Long, Jenny
Xiao, Jianjun
Destenaves, Benoit
Gao, Lei
Sahmoud, Tarek
Gualberto, Antonio
Juric, Dejan
CANCER RESEARCH, 2022, 82 (04)
[8] Phase I/II trial of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer
Hamilton, Erika P.
Wang, Judy S.
Pluard, Timothy
Johnston, Stephen
Morikawa, Aki Aki
Dees, Claire E.
Jones, Robert H.
Haley, Barbara
Armstrong, Anne
Cohen, Adam L.
Munster, Pamela
Wright, Gail
Kayali, Fadi
Korpal, Manav
Yu, Lihua
Cantagallo, Lisa
Destenaves, Benoit
Zhang, Zhaojie
Gao, Lei
Pipas, Marc J.
Sahmouud, Tarek
Gualberto, Antonio
Juric, Dejan
CANCER RESEARCH, 2021, 81 (04)
[9] Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer
Smith, Peter G.
Puyang, Xiaoling
Furman, Craig
Zheng, Guo Zhu
Banka, Deepti
Thomas, Michael
Subramanian, Vanitha
Irwin, Sean
Larsen, Nicholas
Caleb, Benjamin
Karr, Craig
Wu, Jeremy
O'Shea, Morgan
Yang, Joyce
Davis, Allison
Kim, Amy
Rioux, Nathalie
Rimkunas, Victoria
Yao, Huilan
MacKenzie, Crystal
Kumar, Pavan
Smith, Sherri
Eckley, Sean
Hart, Andrew
Lai, George
Rowbottom, Christopher
Fekkes, Peter
Buonamici, Silvia
Reynolds, Dominic
Yu, Lihua
Sahmoud, Tarek
Warmuth, Markus
Mitchell, Lorna
Zhu, Ping
Korpal, Manav
CANCER RESEARCH, 2017, 77
[10] A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER plus ) breast cancer.
Ebbinghaus, S.
Blum, J. L.
Cortes, J.
Rugo, H. S.
Swanton, C.
Eaton, L.
Song, Y.
Zhang, T.
Baselga, J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →